Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.31 |
| ▸ | LMNA | P02545 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | GMNN | O75496 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058523 | 1.00 | TRPV1 (0.33) | TRPV1ASAH2MEN1KMT2ACYP3A4 | |
| SCHEMBL951986 | 0.75 | TRPV1 (0.50) | TRPV1ASAH2MEN1KMT2ACYP3A4 | |
| SCHEMBL6058525 | 0.75 | TRPV1 (0.50) | TRPV1ASAH2MEN1KMT2ACYP3A4 | |
| SCHEMBL28245143 | 0.75 | TRPV1 (0.36) | TRPV1ASAH2MEN1KMT2ACYP3A4 | |
| SCHEMBL2162625 | 0.75 | — | — | |
| SCHEMBL2162626 | 0.75 | — | — | |
| SCHEMBL7287791 | 0.73 | FAAH (0.54) | TRPV1MEN1KMT2ACYP3A4PTGS1 | |
| SCHEMBL7353526 | 0.73 | FAAH (0.48) | TRPV1MEN1KMT2ACYP3A4PTGS1 | |
| SCHEMBL2162598 | 0.73 | HMGCR (0.35) | TRPV1MEN1KMT2ACYP3A4PTGS1 | |
| SCHEMBL2162600 | 0.73 | HMGCR (0.35) | TRPV1MEN1KMT2ACYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456588-B | Methods for the microbial production of capsaicinoids using capsaicin synthase | 科纳根公司 | 2021-04-30 | — | — | CN | claimed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | claimed |
| EP-2460405-B1 | EPIGALLOCATECHIN GALLATE DERIVATIVE AS ANTIBACTERIAL AGENT | UNIV OSAKA (JP) | 2015-03-18 | — | — | EP | claimed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | claimed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | claimed |
| CN-106456588-B | Methods for the microbial production of capsaicinoids using capsaicin synthase | 科纳根公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10655150-B2 | Methods of making capsinoids by biosynthetic processes | CONAGEN INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190010522-A1 | METHODS OF MAKING CAPSINOIDS BY BIOSYNTHETIC PROCESSES | CONAGEN INC. (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3377057-A1 | METHODS OF MAKING CAPSINOIDS BY BIOSYNTHETIC PROCESSES | Conagen Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9901565-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | disclosed |
| WO-2017120473-A1 | METHODS OF MAKING CAPSINOIDS BY BIOSYNTHETIC PROCESSES | CONAGEN INC. (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-1069105-B1 | CAPSAICINOIDE-LIKE SUBSTANCES HAVING ESTER BOND | AJINOMOTO KK (JP) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006038049-A1 | A SPRAY FORMULATION FOR PUNGENCY ENHANCEMENT IN CAPSICUM | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-04-13 | — | — | WO | disclosed |
| US-20060073121-A1 | Spray formulation for pungency enhancement in Capsicum | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-04-06 | — | — | US | disclosed |
| US-6333421-B1 | SUBSTANCES HAVING IMMUNOPOTENTIATING AND ENERGY METABOLISM ENHANCING ACTIVITY | MORINAGA & CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1069105-A1 | NOVEL CAPSAICINOIDE-LIKE SUBSTANCES HAVING ESTER BOND | MORINAGA & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060073121-A1 | Spray formulation for pungency enhancement in Capsicum | CYP51A1, CAPG, CAPRIN1 | TRPV1 105/4885ASAH2 165/4885MEN1 4639/4885 |
| US-20190010522-A1 | METHODS OF MAKING CAPSINOIDS BY BIOSYNTHETIC PROCESSES | FADS2, COASY, FASN | TRPV1 1857/4885ASAH2 116/4885MEN1 3280/4885 |
| US-10655150-B2 | Methods of making capsinoids by biosynthetic processes | FADS2, COASY, FASN | TRPV1 1857/4885ASAH2 116/4885MEN1 3280/4885 |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | TEAD4, ELOVL6, TEAD1 | TRPV1 734/4885ASAH2 3144/4885MEN1 4331/4885 |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | TRPV1 764/4885ASAH2 3018/4885MEN1 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.